PET/CT Imaging of Human TNFα Using [89Zr]Certolizumab Pegol in a Transgenic Preclinical Model of Rheumatoid Arthritis
- 7 May 2019
- journal article
- research article
- Published by Springer Nature in Molecular Imaging and Biology
- Vol. 22 (1) , 105-114
Abstract
Tumor necrosis factor alpha (TNFα) drives inflammation and bone degradation in patients with rheumatoid arthritis (RA). Some RA patients experience a rapid clinical response to TNFα inhibitors such as certolizumab pegol (CZP) while other patients show limited to no response. Current methods for imaging RA have limited sensitivity and do not assist in the selection of patients most likely to respond to immune-mediated therapy. Herein, we developed a novel positron emission tomography (PET) radiotracer for immuno-PET imaging of TNFα in transgenic human TNFα-expressing mice.Keywords
This publication has 24 references indexed in Scilit:
- Similar Improvements in Patient-Reported Outcomes Among Rheumatoid Arthritis Patients Treated with Two Different Doses of Methotrexate in Combination with Adalimumab: Results From the MUSICA TrialRheumatology and Therapy, 2018
- 99mTc-labelled S-HYNIC certolizumab pegol in rheumatoid arthritis and spondyloarthritis patients: a biodistribution and dosimetry studyEJNMMI Research, 2016
- Comparative effectiveness of biologics for the management of rheumatoid arthritis: systematic review and network meta-analysisClinical Rheumatology, 2016
- Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challengesNature Reviews Rheumatology, 2015
- Predicting future response to certolizumab pegol in rheumatoid arthritis patients: Features at 12 weeks associated with low disease activity at 1 yearArthritis Care & Research, 2012
- Certolizumab PegolmAbs, 2010
- Monitoring anti-TNFα treatment in rheumatoid arthritis: responsiveness of magnetic resonance imaging and ultrasonography of the dominant wrist joint compared with conventional measures of disease activity and structural damageAnnals of the Rheumatic Diseases, 2009
- The PREMIER study: A multicenter, randomized, double‐blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatmentArthritis & Rheumatism, 2005
- Development of anti-TNF therapy for rheumatoid arthritisNature Reviews Immunology, 2002
- Anti-TNFα Therapy of Rheumatoid Arthritis: What Have We Learned?Annual Review of Immunology, 2001